S ary The semiautomated fluorimetric microculture cytotoxicity assay (FMCA) 
Multidrug resistance (MDR) defines a cellular phenotype in which the development of resistance in vitro to one cytotoxic drug confers cross-resistance to other structurally and fumctionally dissimilar drugs (Borst, 1991; Kalken et al., 1991) . The resistance pattern of the classical MDR phenotype often includes the anthracyclines and the vinca alklaloids and is often associated with increased expression of the membrane-bound 170 kDa P-glycoprotein (Pgp) , coded for by the MDR] gene. Pgp is believed to function as an ATPdependent efflux protein that actively extrudes the drugs from the tumour cell (Borst, 1991; Kalken et al., 1991) . For at least some tumour types, Pgp has been implicated in clinical drug resistance and prognosis (van Kalken et al., 1991) .
In vitro, MDR may be circumvented by a variety of noncytotoxic agents, including calcium channel blockers, cyclosporins, phenothiazines, neuroleptics and cephalosporins (Ford & Hait, 1990) . The prospect of reversing MDR in the clinical setting has therefore attracted considerable interest, and some clinical pilot studies using verapamil have been promising (Dalton et al., 1989; Miller et al., 1991) . Although verapamil is probably the most well-studied resistance modifier (RM), cardiovascular side-effects preclude its clinical use at in vitro active concentrations (Pennock et al., 1991) . Cyclosporin A (CsA), on the other hand, has been shown to reverse resistance in vitro at concentrations readily achievable in vivo without serious toxic effects (Twentyman, 1988; Sonneveld et al., 1992) . Furthermore, a non-immunosuppressive cyclosporin analogue denoted SDZ PSC 833 (PSC) was recently found to be 10-fold more potent than CsA as an RM in MDR cell lines (Gaveriaux et al., 1991) . The cyclosporins may thus be well suited for testing the concept of resistance modification in the clinic. Indeed, some preliminary studies have indicated clinical resistance-modifying activity of CsA in myeloma (Sonneveld et al., 1992) and acute myelocytic leukaemia (AML; List et al., 1993) , and phase II trials of both CsA and PSC are ongoing.
Recently some preliminary evidence was published suggesting that diagnosis-specific activity could be accurately detected in accordance with clinical experience by nonclonogenic drug resistance assays based on measurement of cell kill in the whole tumour cell population (Weisenthal, 1991; Weisenthal et al., 1991) . Corroborating these findings, we have recently found that the FMCA retrospectively can detect diagnosis-specific drug activity for a series of standard drugs (Nygren et al., 1993) and prospectively for 2-chlorodeoxyadenosine (CdA) and taxol (submitted for publication). The present study was therefore undertaken to investigate the relative tumour type-specific resistance-modifying activity of CsA and PSC in combination with doxorubicin (Dox) or vincristine (Vcr) in vitro, using a broad spectrum of tumour diagnoses.
Materias ad methods
Twnour samples and cell preparation A total of 322 tumour samples from patients with AML, acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myelocytic leukaemia (CML), myeloma, non-Hodgkin's lymphoma (NHL) or different types of solid tumours were included in the study. The samples were obtained from routine surgery, diagnostic biopsy or bone marrow/peripheral blood sampling. In some cases tumour sampling was performed for in vitro drug sensitivity testing only, which was approved of by the research ethical committee at the Uppsala University Hospital. The number and characteristics of the samples are detailed in Table I . Tumour tissue from solid tumours was minced into 1 mm3 pieces and tumour cells were then isolated by collagenase dispersion and Percoll (Kabi-Pharmacia, Uppsala, Sweden) density gradient centrifugation as described previously (Nygren & Larsson, 1991) . Leukaemic cells were obtained from bone marrow or peripheral blood by 1.077 g ml-' Ficoll-Paque (Kabi-Pharmacia) density gradient centrifugation (Larsson et al., 1992a) . Viability was determined by trypan blue exclusion test and the proportion of tumour cells was judged by inspection of May-GriinwaldGiemsa-stained cytocentrifuge preparations by a trained cytopathologist.
Culture medium RPMI-1640 (Northumbria Biologicals, Cramlington, UK) supplemented with 10% heat-inactivated fetal calf serum (FCS; Northumbria), 2 mM glutamine, 50Lg ml-' streptomycin and 60 ig ml ' penicillin (Northumbria) was used throughout. Cells were cryopreserved in culture medium containing 10% dimethyl sulphoxide (DMSO; Sigma, St Louis, MO, USA) and 50% FCS by initial freezing for 24 h at -70'C followed by storage in liquid nitrogen. Both fresh and cryopreserved samples were used in this study.
Reagents and drugs
Fluorescein diacetate (FDA; Sigma) was dissolved in DMSO and kept frozen (-20'C) as a stock solution (lOmgml-') protected from light. CsA and PSC, provided by P. Anderson (Sandoz, Basle, Switzerland), were dissolved in absolute ethanol-phosphate-buffered saline (PBS) and further diluted in PBS. The final concentration of ethanol never exceeded 0.1%, which had no effect on cell survival. Dox was obtained from Farmitalia Carlo Erba (Milan, Italy) and Vcr from Lilly (Giessen, Germany). CsA and PSC were generally tested at two concentrations, 1 and 3 ;Lg ml', whereas Dox and Vcr were tested at 0.5 and 0.1 Lg ml-' respectively, cut-off concentrations empirically derived (EDCCs) as previously described (Larsson et al., 1992a Cytotoxicity assay procedure The principal steps of the FMCA procedure have been described previously (Larsson et al., 1992a) . The assay is based on measurement of fluorescence generated from hydrolysis of FDA to fluorescein by cells with intact plasma membranes.
On day 1 180IL per well of the tumour cell preparation (0.5-5 x 1IO cells per ml of culture medium) was seeded into the wells of V-shaped 96-well microtitre plates (Nunc, Roskilde, Denmark) prepared as described above. Six blank wells received only culture medium and six wells with cells, but without drugs, served as control. The plates were then incubated at 37C in a humidified atmosphere containing 95% air and 5% carbon dioxide. At the end of the incubation period (72 h), the medium was removed and the cells washed with PBS. PBS at I00 Il per well containing FDA (10L.g ml-') was then added columnwise to control, experimental and blank wells and the plates were incubated for 1 h before reading the fluorescence in the Fluoroscan 2. The fluorimeter was blanked against wells containing PBS including the dye but without cells. 
Quantification of FMCA results
The results obtained by the indicator FDA are presented as survival index (SI), defined as the fluorescence of experimental cultures expressed as a percentage of that of control cultures with blank values subtracted. Since for each sample the single drugs and the combinations were tested on the same microtitre plate, and since the CV in test wells is independent of the SI level, the mean intra-assay CV (CV in controls within a plate) was used to define response to RMs. The RM response rate was thus defined as the proportion of samples showing a >25% (2-3 times mean intra-assay CV in controls) decrease in SI for Dox or Vcr after addition of RM at the EDCC in a particular sample, and was divided into two groups, a 25-50% (+) and a >50% (4-5 times mean control CV) decrease (+ +). Drug interaction analysis was performed using the multiplicative concept (Valeriote & Lin, 1975) , in which the effect of an additive combination is expected to be equal to the product of the effect of its constituents, whereas synergy is observed when the effect is greater than this product. Thus, for a two-drug additive combination composed of single agents with SI values of 50% and 40%, the combination would be expected to result in an SI value of 20% (0.5 x 0.4). The ratio of observed SI values and those expected according to an additive interaction model was then calculated and observed/expected ratios <0.8 were defined as synergistic interactions (Ying Tan et al., 1988) . In some analyses the cytotoxicity data for Dox were divided into three groups based on the median SI value and standard deviation (s.d.) category has a probability of clinical response to the particular drug higher than expected, IDR a lower and EDR an extremely low probability of response (Bosanquet, 1991; Larsson & Nygren, 1993) .
Statistical analysis SI values were compared using the Student's t-test. Correlations were performed using Pearson's correlation coefficient and differences in proportions were analysed by the approximate normal test for comparison of proportions (Colton, 1974) . The level of significance was set to P<0.05.
Results
Effect of single drugs The effects of Dox, Vcr, CsA and PSC on SI for haematological and solid tumours are shown in Figure 1 . For Dox and Vcr mean values ± standard error of the mean (s.e.m.) for all samples were 53 ± 1.7 and 70 ± 1.5 respectively. The group of haematological samples showed lower mean SI values than the solid tumour group in response to Dox (42 ± 1.7 and 83 ± 2.8 respectively) and Vcr (66± 1.7 and 87 ± 2.5) and these differences were highly significant (P<0.001). At 1 ggml-' CsA or PSC little or no effect was discernible for any of the tumour groups. At 3 pg ml-, CsA showed increased activity in NHL/CLL and AML/CML/ myeloma with mean SI values of 79 ± 8.3 and 82 ± 3.4 respectively. At this concentration 22% of the NHL/CLL samples had an SI <50%, which should be compared with the 0% and 10% for the solid and AML groups respectively Fgwe Slightly weaker correlations were noted for CsA at 3 iLg ml-' (Table IV) .
Relationship to previous treatment In Figure 2 RMs. A tendency to increasing response rates in the treated category was observed, and the differences were statistically significant for the combinations Dox + PSC 3 g ml-' and Vcr + I or 3 ig ml -' CsA or I pg ml-' PSC (P <0.05).
Relationship to cytotoxic drug sensitivity In Table V the samples were divided into LDR, IDR and EDR groups with mgard to Dox sensitivity. The highest RM response rates were found in the LDR category followed by IDR and EDR. In the EDR group significantly lower resistance-modifying activity than in both the LDR group (P<O.OOl) and the IDR group (P<0.05) was observed for Dox + CsA 1 and 3 Lg ml ' and Dox + PSC 3 Lg mlP'.
Between the LDR and IDR groups statistical difference was observed for Dox + PSC I ug mli (P <0.05).
In the present study the RM effects were measured at fixed concentrations of the chemotherapeutic drugs instead of measuring changes in the concentration required to achieve a fixed effect (i.e. IC5), a procedure often used in experiments on drug-resistant cell lines. One reason was that from many of the samples not enough tumour cells were obtained to permit detailed dose-response analysis. Measuring variable effects at a fixed dose in highly heterogeneous patient populations also resembles the clinical phase II setting. The concentrations used were carefully chosen to produce maximal scatter of SI values in a large panel of samples in order to have the highest probability to distinguish sensitive from resistant samples (Larsson et al., 1992a) . Furthermore, the individual intra-assay variation (CV) was used to statistically define the response criteria. Since the primary objective was to investigate the relative subpanel specificity of RM effects under identical in vitro conditions, we find the present approach adequate for that purpose.
At I ytg mn' CsA and PSC, the cyclosporins alone had little effect, whereas at 3 iLg ml1 ' a small cytotoxic effect was noted in the haematological tumours. For CsA this was most apparent in the CLL/NHL group, which is in accordance with a previous study (Larsson et al., 1992h) . In the majority of cases the effect of the cyclosporins alone could not explain the effect observed for the combinations since there was a close correspondence between the percentage decrease in cytotoxic drug-induced SI after addition of RM and the calculated observed/expected ratios according to the multiplicative concept for drug interactions. (Chan et al., 1990 (Chan et al., , 1991 (Nooter & Herweijer, 1991) , but showed little response to RM addition in the present study. In contrast, ALL, dominated by paediatric samples, showed high response rates to CsA and PSC but has been reported to express the Pgp in only a small fraction of cases (Pieters et al., 1992) . However, the role of Pgp in childhood ALL still appears controversial (Gosauguen et al., 1993) .
Clinical documentation on the RM efficacy of cyclosporins is sparse. In a study of CsA + vinblastine given to 22 patients with renal cell carcinoma, no responses were observed (Rodenburg et al., 1991) . In a trial of 23 patients with metastatic colon carcinoma only 1 out of 23 responded with a partial remission to an epirubicin + CsA combination (Murren et al., 1991) . In AML, on the other hand, good responses were reported for patients resistant and refractory to AraC + daunorubicin after addition of CsA (List et al., 1993) . Promising tumour responses were also obtained in myeloma patients using VAD (Vcr+ Dox+prednisolone) + CsA (Sonneveld et al., 1992) . Furthermore, in a recent literature review of clinical investigations of MDR-reversing agents, presenting results from more than 350 treated patients, many leukaemias, lymphomas and myelomas were considered to be potentially responsive whereas, in solid tumour types, only a few patients appeared to benefit from the RM treatment (Raderer & Scheithauer, 1993 (Gaveriaux et al., 1991; Jonsson et al., 1992) , but not all (Friche et al., 1992) (Slovak et al., 1993) . The fact that some of the tumour types originating from Pgp-expressing tissues, and which are known to express high Pgp levels, do not show any response to PSC and CsA clearly indicates that RM-insensitive mechanisms of resistance are also important, at least for these types of tumours. In this context, one should note that clinically achievable steady-state concentrations of CsA correspond to the in vitro concentrations tested (1-31g ml-') (Sonneveld et al., 1992) .
The Dox and Vcr concentrations used (EDCCs) correspond roughly to the clinically achievable peak plasma concentration (Alberts & Chen, 1980 Although a tendency to an increased resistance-modifying activity was observed in samples from previously treated patients, the response rate of those from untreated patients was also substantial. Interestingly, the highest response rates to RMs were found in the most drug-sensitive group of samples, the LDR group, whereas the EDR group showed significantly lower response rates. The low frequency of responders to RMs in the EDR population thus further underlines the virulent nature of this in vitro-defined type of resistance 
